Forest Laboratories (FRX) continued to benefit from the news of its acquisition by Actavis PLC, the world’s second largest generic drug maker.
From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.